Cantor Fitzgerald restated their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a research note released on Friday. They currently have a $55.00 price target on the biopharmaceutical company’s stock.

“We rate TBPH 12-month price target of $55. We believe the Street is underestimating the peak sales potential of its four key programs (JAK Inhibitor, NEP Inhibitors, TD-9855, Revefenacin), all of which have data expected this year. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55. The Disclosure Section may be found on pages 3 – 5.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55. Our DCF analysis arrives at a 12-month share price of $60.”,” the firm’s analyst commented.

TBPH has been the topic of a number of other reports. Leerink Swann set a $38.00 price objective on Theravance Biopharma and gave the company a buy rating in a research note on Wednesday. Needham & Company LLC restated a buy rating and issued a $40.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, August 1st. ValuEngine cut Theravance Biopharma from a buy rating to a hold rating in a research note on Thursday, November 1st. BidaskClub upgraded Theravance Biopharma from a hold rating to a buy rating in a research note on Friday, September 28th. Finally, Piper Jaffray Companies restated a buy rating on shares of Theravance Biopharma in a research note on Tuesday, October 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $47.00.

Theravance Biopharma stock traded up $1.26 during midday trading on Friday, reaching $25.81. The stock had a trading volume of 463,648 shares, compared to its average volume of 253,338. Theravance Biopharma has a 12 month low of $21.27 and a 12 month high of $35.48. The stock has a market capitalization of $1.30 billion, a P/E ratio of -4.74 and a beta of 2.09. The company has a debt-to-equity ratio of 6.52, a quick ratio of 3.95 and a current ratio of 4.14.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.18) by $0.08. Theravance Biopharma had a negative return on equity of 355.48% and a negative net margin of 513.41%. The business had revenue of $12.84 million for the quarter, compared to analysts’ expectations of $10.55 million. Equities research analysts forecast that Theravance Biopharma will post -4.26 EPS for the current fiscal year.

In other news, SVP Philip D. Worboys sold 6,393 shares of the company’s stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $28.50, for a total transaction of $182,200.50. Following the sale, the senior vice president now directly owns 166,753 shares in the company, valued at $4,752,460.50. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Bradford J. Shafer sold 7,119 shares of the company’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $27.71, for a total value of $197,267.49. Following the sale, the executive vice president now owns 84,000 shares in the company, valued at $2,327,640. The disclosure for this sale can be found here. Insiders sold a total of 57,255 shares of company stock worth $1,551,343 over the last 90 days. 6.10% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Woodford Investment Management Ltd increased its position in shares of Theravance Biopharma by 2.9% during the second quarter. Woodford Investment Management Ltd now owns 11,213,879 shares of the biopharmaceutical company’s stock valued at $254,331,000 after buying an additional 315,000 shares during the period. BlackRock Inc. increased its position in shares of Theravance Biopharma by 2.2% during the third quarter. BlackRock Inc. now owns 3,833,409 shares of the biopharmaceutical company’s stock valued at $125,239,000 after buying an additional 82,620 shares during the period. Northern Trust Corp increased its position in shares of Theravance Biopharma by 3.6% during the second quarter. Northern Trust Corp now owns 535,284 shares of the biopharmaceutical company’s stock valued at $12,140,000 after buying an additional 18,733 shares during the period. Chescapmanager LLC increased its position in shares of Theravance Biopharma by 15.0% during the second quarter. Chescapmanager LLC now owns 403,321 shares of the biopharmaceutical company’s stock valued at $9,147,000 after buying an additional 52,690 shares during the period. Finally, State of New Jersey Common Pension Fund D increased its position in shares of Theravance Biopharma by 17.7% during the second quarter. State of New Jersey Common Pension Fund D now owns 265,459 shares of the biopharmaceutical company’s stock valued at $6,021,000 after buying an additional 40,000 shares during the period. Hedge funds and other institutional investors own 84.74% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Featured Story: Bond

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.